Diagnostic Translational Considerations for Global Health Settings: Portable Detection of Human Papillomavirus for Cervical Cancer Screening in India
JCO Global Oncology · 2025
DOI: 10.1200/go-25-00117 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Vi T Nguyen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biodesign Institute, Arizona State University, Tempe, AZ. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Early Detection of Cancer, Papillomavirus Infections, Papillomaviridae. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Translation of diagnostic technology developed at the laboratory bench involves iterations of user feedback and design modifications. Learning about translational requirements early in the design process facilitates the development of feasible prototypes that have a better likelihood of implementation in global health settings. During our development of a portable system to detect human papillomavirus (HPV) for cervical cancer screening in India, we encountered and solved issues related to research translation. We report our findings to help others deploying diagnostic technology for global health. MATERIALS AND METHODS We designed a point-of-care system to process patient samples and diagnose HPV infection in the cervix. We continually shipped components of the system from the United States to our collaborating team in India to assess component condition and usability at the local site. We simultaneously developed HPV isothermal amplification assays that were fit for purpose. Cervical brush samples were used in our portable system for functional validation. RESULTS We found ideal transport methods to ensure component quality and reagent stability through the international shipment chain. Portable systems should be designed as simple as possible for correct usage at the local testing site. Usability tests drove our design improvements from 28% to 93% success rates. We demonstrated proof-of-concept functionality of our portable system for 13 cervical brush samples on-site, with a sensitivity of 100% and specificity of 88.9%. CONCLUSION Issues related to technology transfer for global health settings manifest during distribution and deployment of prototypes. We identified several issues during our synergistic design process and report recommendations on the basis of our experience.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Biodesign Institute, Arizona State University, Tempe, AZ.
- All India Institute of Medical Sciences, New Delhi, India.
- University of Michigan, Ann Arbor, MI.
- Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
ORCID-Profile: Vi T Nguyen, Pankaj Kumar, Joshua Eger, Neerja Bhatla, Karen S Anderson
Förderung
- NCI NIH HHS
Zitieren
APA
Nguyen, V. T., Arockiam, S., Kumar, P., Eger, J., Herman, K., Vashist, S., Bhatla, N., Dar, L., Brenner, D. E., Anderson, K. S., & Blain Christen, J. (2025). Diagnostic Translational Considerations for Global Health Settings: Portable Detection of Human Papillomavirus for Cervical Cancer Screening in India. JCO Global Oncology. https://doi.org/10.1200/go-25-00117
Vancouver
Nguyen VT, Arockiam S, Kumar P, Eger J, Herman K, Vashist S, et al. Diagnostic Translational Considerations for Global Health Settings: Portable Detection of Human Papillomavirus for Cervical Cancer Screening in India. JCO Global Oncology. 2025. doi:10.1200/go-25-00117
BibTeX
@article{Nguyen2025,
author = {Nguyen, Vi T and Arockiam, Siril and Kumar, Pankaj and Eger, Joshua and Herman, Kirk and Vashist, Shachi and Bhatla, Neerja and Dar, Lalit and Brenner, Dean E and Anderson, Karen S and Blain Christen, Jennifer},
title = {Diagnostic Translational Considerations for Global Health Settings: Portable Detection of Human Papillomavirus for Cervical Cancer Screening in India},
journal = {JCO Global Oncology},
year = {2025},
doi = {10.1200/go-25-00117}
}
EUVIMED